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Abstract
Background: The atypical antipsychotic clozapine is effective in treatment-resistant schizophrenia; however, the success or 
failure of clozapine therapy is substantially affected by the variables that impact the clozapine blood concentration. Thus, 
elucidating the inter-individual differences in clozapine pharmacokinetics can facilitate the personalized therapy.
Methods: Since a potential role in clozapine metabolism is assigned to CYP1A2, CYP2C19, CYP2D6 and CYP3A enzymes, the 
association between the patients’ CYP status (CYP genotypes, CYP expression) and clozapine clearance was evaluated in 92 
psychiatric patients.
Results: The patients’ CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine 
serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration 
(185.53 ± 56.53 in low expressers vs 78.05 ± 29.57 or 66.52 ± 0.25 (ng/mL)/(mg/kg) in normal or high expressers, P < .0001), in 
particular that the patients expressed CYP1A2 at a relatively low level. The functional CYP3A5*1 allele seemed to influence 
clozapine concentrations in those patients who expressed CYP3A4 at low levels. The dose requirement for the therapeutic 
concentration of clozapine was substantially lower in low CYP3A4 expresser patients than in normal/high expressers 
(2.18 ± 0.64 vs 4.98 ± 1.40 mg/kg, P < .0001). Furthermore, significantly higher plasma concentration ratios of norclozapine/
clozapine and clozapine N-oxide/clozapine were observed in the patients displaying normal/high CYP3A4 expression than 
in the low expressers.
Conclusion: Prospective assaying of CYP3A-status (CYP3A4 expression, CYP3A5 genotype) may better identify the patients 
with higher risk of inefficiency or adverse reactions and may facilitate the improvement of personalized clozapine therapy; 
however, further clinical studies are required to prove the benefit of CYP3A testing for patients under clozapine therapy.
Keywords: personalized clozapine therapy, CYP3A4 expression, CYP3A5 genotype, CYP1A2 expression
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Introduction
Clozapine, the prototype of second-generation antipsychot-
ics, is efficacious against both positive and negative symptoms 
of schizophrenia and potently reduces aggression and the risk 
of suicide. It is proved to be effective for therapy of treatment-
resistant patients (Lally et al., 2016). The CATIE study found that 
switching to clozapine after therapeutic failure was more effec-
tive than to any other newer antipsychotic (McEvoy et al., 2006), 
and the SOHO program confirmed the superiority of clozapine 
over other antipsychotics (Attard et al., 2012). However, there are 
some adverse effects; for example, weight gain, increased fasting 
glucose concentration, seizures, and sedation are more common 
with clozapine than with other atypical antipsychotics (Asenjo-
Lobos et  al., 2010). Monitoring of hematological parameters is 
obligatory because of the risk for agranulocytosis (Ng et al., 2014). 
The plasma concentration of clozapine rather than the dose is in 
close association with most side effects. The incidence of adverse 
events is more frequent in patients with plasma concentrations 
>750 ng/mL (Ulrich et al., 2003). At the same dose, considerable 
variability in clozapine concentration has been observed, which 
is attributed to the substantial inter-individual differences in clo-
zapine metabolism (Couchman et al., 2010); therefore, therapeu-
tic drug monitoring is highly recommended (Hiemke et al., 2011).
Clozapine is extensively metabolized forming two major 
metabolites, the pharmacologically active norclozapine and the 
inactive clozapine N-oxide as well as minor hydroxylated metabo-
lites (Dain et  al., 1997). Norclozapine contributes to the unique 
antipsychotic profile of clozapine with low risk for extrapyramidal 
side effects and improvement of cognitive function; however, it has 
some attributes distinct from those of the parent compound (nor-
clozapine: D2/D3 partial agonist, clozapine: D2/D3 inverse agonist/
antagonist) (Lameh et  al., 2007). Various cytochrome P450 (CYP) 
enzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4) have been demon-
strated to be involved in clozapine metabolism; however, the clini-
cal relevance of these enzymes has to be clarified. CYP3A4 seems 
to catalyze N-oxidation of clozapine, whereas the formation of nor-
clozapine appears to be more complex (Linnet and Olesen, 1997). 
CYP1A2 and CYP3A4 were assumed to be the major enzymes 
responsible for the N-demethylation pathway (Fang et al., 1998), 
and several clinical reports provided indirect evidence for their 
participation in clozapine metabolism. Concomitant treatment 
with fluvoxamine, the potent inhibitor of several CYPs (CYP1A2, 
CYP2C19, CYP3A4), significantly decreased the plasma norclozap-
ine/clozapine ratios and patients’ clozapine dose requirement (Lu 
et al., 2000; Jones et al., 2007). Cigarette smoking, inducing CYP1A2 
expression, seems to increase clozapine clearance; however, 
CYP1A2 genetic polymorphisms do not have significant clinical 
effect (Weide et al., 2003). In vitro studies have demonstrated that 
at high clozapine concentrations, CYP3A4 plays a primary role in 
N-demethylation (Olesen and Linnet, 2001; Eiermann et al., 1997, 
Fang et al., 1998). The relative importance of CYP2C19 in clozapine 
N-demethylation was demonstrated in vitro (Linnet and Olesen, 
1997; Fang et al., 1998), and a minor role of CYP2D6 in metabolic 
pathways other than N-demethylation was assumed (Fischer et al., 
1992; Olesen and Linnet, 2001). A possible contribution of CYP2C19 
to in vivo clozapine metabolism was suggested by Jaquenoud-Sirot 
et al. (2009); however, in vivo investigations by Dahl et al. (1994) and 
Ghassabian et al. (2010) failed to confirm the correlation between 
the CYP2C19 or CYP2D6 phenotypes and the serum clozapine con-
centrations or the norclozapine/clozapine ratio.
CYP activities can display more than 100-fold inter-individ-
ual variability (Temesvári et  al., 2012), which is partly attributed 
to genetic factors. Genetic polymorphisms of CYP enzymes can 
explain some differences in clozapine metabolism; however, non-
genetic factors (hormones, diseases, age, medication, smoking) 
can modify CYP activities, resulting in transient poor (or extensive) 
metabolism. The genotype determines the potential for the expres-
sion of functional or nonfunctional CYP enzyme, whereas non-
genetic factors give rise to altered phenotypes. Homozygous wild 
genotype, predicted to be translated to CYP enzyme with normal 
function, may be switched into poor (or extensive) metabolism due 
to phenoconversion (Shah and Smith, 2015). Patients’ clozapine-
metabolizing capacity can be estimated by the evaluation of CYP 
genotypes and by CYP expression. We previously described a com-
plex diagnostic system (CYPtest) that determines drug metaboliz-
ing capacity by CYP genotyping and by the current CYP expression 
in leukocytes. CYP3A4 and CYP1A2 mRNA levels in leukocytes were 
proven to inform about the hepatic CYP3A4 and CYP1A2 activities 
(Temesvári et  al., 2012). Information on patients’ CYP status can 
refine the personalized clozapine therapy, facilitating the appropri-
ate dosage, and can predict the risk of outlying from the therapeutic 
concentration range.
The goals of the present study were to estimate the asso-
ciation between the patients’ drug-metabolizing capacity (CYP 
expressions and CYP genotypes) and their clozapine therapy 
(dose, clozapine levels), and to analyze the influence of CYP-
status on the patients’ dose requirements, which can contribute 
to the improvement of patients’ personalized medication.
METHODS
Patients
Ninety-two inpatients at the Department of Psychiatry and 
Psychotherapy, Semmelweis University (Budapest, Hungary) were 
enrolled. The patients on stable clozapine therapy for at least 2 weeks 
were included in the study. Written informed consent was obtained 
Significance Statement
Inter-individual variability of cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C19, CYP2D6) has been attributed to 
substantial differences in clozapine plasma concentrations and in drug response. The patients’ CYP2C19 and CYP2D6 
genotypes appeared to have no effect on steady-state clozapine concentrations, even as CYP1A2 expression influenced 
neither the clozapine levels nor the norclozapine/clozapine ratio. The relative importance of these enzymes in clozapine 
clearance seemed to be lower, whereas the patients’ CYP3A-status (CYP3A4 expression and CYP3A5 genotype) was 
found to potentially influence normalized clozapine concentration and dose requirement, in particular that the patients 
expressed CYP1A2 at a relatively low level. For the optimal plasma concentrations (200–600 ng/mL), CYP3A-status guided 
clozapine dosing was proposed (4.98  mg/kg for the normal/high CYP3A4 expressers and CYP3A5*1 carriers, whereas 
2.18 mg/kg for low CYP3A4 expressers). Personalized medication taking patients’ CYP3A status into account may facilitate 
the improvement of individual clozapine therapy, leading to the dosage optimization for a more effective therapy.
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from all participants. The study was approved by the Hungarian 
Committee of Science and Ethics. Patients’ demographic data and 
medication was recorded (Table 1). Of 92 patients, 18 patients were 
prescribed clozapine as monotherapy, whereas the majority of the 
patients received concomitant medications (haloperidol, risperi-
done, aripiprazole, or amisulpride) or anticonvulsant drugs (clon-
azepam, valproic acid, or lamotrigine) as adjunctive therapy. Nearly 
one-half of the patients (n = 41) received beta-adrenergic blockers 
(propranolol or metoprolol). The clozapine therapy was applied 
according to the conventional clinical protocol, initiated at low 
dosage (12.5–25 mg/d), and subsequently titrated in increments of 
12.5 to 50 mg/d until the optimal response was achieved.
Assaying CYP status
Patients’ CYP status was determined by CYP2C19, CYP2D6, 
CYP3A4, and CYP3A5 genotyping and by analyzing CYP1A2 and 
CYP3A4 expression in leukocytes. Genomic DNA and leukocytes 
were isolated from the peripheral blood samples as previously 
described by Temesvári et al. (2012). Hydrolysis single-nucleotide 
polymorphism analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4, 
CYP2C19*17, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, 
CYP2D6*41, CYP3A4*1B, CYP3A4*22, and CYP3A5*3 was per-
formed using TaqMan probes (BioSearch Technologies, Novato, 
CA). CYP2D6*5 (gene deletion) and CYP2D6 duplication were ana-
lyzed by TaqMan Copy Number Assay (ThermoFisher Scientific, 
Waltham, MA). Since CYP1A2 expression was found to be poorly 
associated with the presence of CYP1A2 SNPs (Ferrari et  al., 
2012), the patients’ CYP1A2 activity was estimated by CYP1A2 
mRNA levels in leukocytes, and not by CYP1A2-genotype.
For assaying CYP expressions, RNA was isolated from leuko-
cytes, reverse transcribed into single-stranded cDNA using the 
Maxima First Strand cDNA Synthesis Kit (ThermoFisher Scientific), 
and then real-time PCR was performed using KAPA Fast Probes 
Mastermix (KAPA Biosystems, Cape Town, South Africa) and 
TaqMan probes. The quantities of CYP1A2 and CYP3A4 mRNAs 
relative to that of the housekeeping gene glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) were determined. GAPDH expres-
sion is constant in all cells and independent of experimental 
conditions; therefore, its expression was set to 1 and CYP mRNA 
levels were normalized by GAPDH expression. Three categories of 
CYP expressions were applied to describe low, normal, and high 
expressers. The cut-off values for CYP mRNA levels in leukocytes 
have been previously established on the basis of the cut-off val-
ues for the hepatic CYP enzyme activities (CYP1A2: phenace-
tin O-dealkylation; CYP3A4: nifedipine oxidation or midazolam 
1’- and 4-hydroxylation). The cut-off values for CYP1A2 (10–5 and 
5*10–4) and CYP3A4 (10–6 and 10–4) allowed a distinction between 
low, normal, and high expressers (Temesvári et al., 2012).
Blood Concentrations of Clozapine and Its 
Metabolites
The blood samples were taken 12 hours after the evening dose 
of clozapine. The steady-state concentrations of clozapine, nor-
clozapine, and clozapine N-oxide were determined by LC-MS/
MS. Chromatographic separation was performed using an Inertsil 
ODS-4 (75 × 2.1 mm, 3 µm) column (GL Sciences Inc., Tokyo, Japan) 
and mobile phases of acetonitrile and 0.1% formic acid in gradient 
running mode. The samples were analyzed using positive electro-
spray ionization and multiple reaction monitoring mode for quan-
titation of the parent compound and its metabolites (m/z 327/270 
and 327/192 for clozapine; m/z 313/270 and 313/192 for norclozap-
ine; m/z 343/256 and 343/192 for clozapine N-oxide). Normalized 
clozapine concentrations were calculated by dividing the concen-
tration values by the corresponding 24-hour dose on a mg/kg basis.
Data Analysis
The statistical significance of demographic data, CYP1A2 and 
CYP3A4 expressions, CYP2C19, CYP2D6 and CYP3A5 genotypes as 
covariates of clozapine, norclozapine and clozapine N-oxide con-
centrations was analyzed by ANOVA using linear model of covar-
iate effects with constant terms. Several mathematical models 
(nonlinear Artificial Neuronal Network and linear with various 
input combinations) were tested to identify the key factor(s) in 
steady-state clozapine concentrations; however, the best models 
for the optimal prediction with the smallest standard deviation of 
model prediction and the smallest number of model parameters 
were all linear. The dose and patients’ CYP3A4 expression were 
identified as significant parameters for clozapine concentration 
Table 1. Patients’ Demographic and Clinical Characteristics
n %
Patients 92
Sex, male/female 38/54 41.3/58.7
Diagnosis
 Schizophrenia 73 79.4
 Schizoaffective disorder 15 16.3
 Other 4 4.3
Current smokers 35 38.0
Age (y), median (min-max) 42 (17–74)
Clozapine daily dose (mg), median 
(min-max)
200 (50–700)
Bodyweight (kg), median (min-max) 76 (51–129)
Serum levels, median (min-max)
 Clozapine (ng/mL) 232 (23–1400)
 Norclozapine (ng/mL) 156 (16–894)
 Clozapine N-oxide (ng/mL) 90 (0–383)
CYP genotype
 CY2C19*
  *1/*1 35 38.0
  *1/mut 23 25
  mut/mut 2 2.2
  mut/*17 6 6.5
  *1/*17 20 21.7
  *17/*17 6 6.5
 CYP2D6**
  *1/*1 36 39.2
  *1/mut 37 40.2
  mut/mut 14 15.2
  *1/*1xN 5 5.4
 CYP3A4
  *1/*1 74 80.4
  *1/*1B 5 5.4
  *1/*22 13 14.2
 CYP3A5
  *1/*3 10 10.9
  *3/*3 82 89.1
CYP expression
 CYP1A2
  low expressers 65 70.7
  normal expressers 27 29.3
 CYP3A4
  low expressers 27 29.3
  normal expressers 62 67.4
  high expressers 3 3.3
*CYP2C19 mut: *2, *3 and *4; **CYP2D6 mut: *3, *4, *5, *6, *10 and *41.
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(P < .0001). The model provided the best prediction when clozap-
ine dose was divided by the patients’ bodyweight.
The statistical model for the clozapine serum concentration 
and for the effects of dose and bodyweight on the concentration 




kclz = +1 0* ,
where cclz is clozapine trough concentration expressed as ng/mL, 
dose is clozapine dose in mg, and bw is bodyweight in kg. Model 
parameters k0 and k1 were estimated for low and normal/high 
CYP3A4 expressers individually. To estimate the optimal dose, 









The lower and upper limits for the optimal dose were estimated 
from the lower and the upper limits of the optimal clozapine 
concentration range of 200 to 600  ng/mL. Matlab R2009b was 
used to perform the analysis and to calculate the optimal dosing.
The data of normalized clozapine concentrations, the 
metabolite/parent drug ratios, and the dose requirements for 
the optimal therapeutic level in the patients were expressed as 
the median and range or mean ± SD. Between-group differences 
were calculated by the use of Kruskal–Wallis ANOVA followed by 
Dunn’s multiple comparisons test. P < .05 was considered to be 
statistically significant.
RESULTS
Patients’ Drug-Metabolizing Capacity and Clozapine 
Exposure
Of 92 patients, 31 carried at least one CYP2C19 loss-of-function 
allele (CYP2C19*2, CYP2C19*3, or CYP2C19*4), and 32 carried the 
gain-of-function CYP2C19*17 allele. CYP2C19 genotype seemed 
to influence neither the clozapine concentrations normalized 
by the dose nor the concentrations normalized by the dose/
bodyweight. No significant differences in clozapine concentra-
tions were observed between the carriers of one or two loss-of-
function alleles and the patients with CYP2C19*1/*1 genotype 
or those with gain-of-function allele (CYP2C19*17) associated 
with increased CYP2C19 expression (P = .1083) (Figure  1A). 
Furthermore, no significant association was found between the 
normalized clozapine concentrations and the patients’ CYP2D6 
genotypes (P = .8881) (Figure 1B).
CYP1A2 expression assays revealed that a substantial por-
tion of the patients (70.7%) was low CYP1A2 expressers and less 
than one-third of the patients expressed CYP1A2 at normal level, 
whereas no high CYP1A2 expresser was found. Smoking is a potent 
inducer of CYP1A2, increasing CYP1A2 expression and enzyme 
activity; however, in the present study, the smoker/nonsmoker 
ratio was the same in the low and normal CYP1A2 expresser 
groups (10:17 vs 25:40, P = 1.00). Furthermore, the normalized clo-
zapine concentrations were comparable in the patients express-
ing CYP1A2 at low and normal level (P = .6639) (Figure 1C).
The role of CYP3A4 in the metabolism of clozapine at thera-
peutic or higher concentrations has been demonstrated; how-
ever, the contribution of the highly polymorphic CYP3A5 must be 
clarified. In the present study, 10 subjects carried the functional 
CYP3A5*1 allele, whereas most of the patients were CYP3A5 non-
expressers (CYP3A5*3/*3) and were therefore expected to lack the 
functional CYP3A5 enzyme. Of 92 patients, 18 carried CYP3A4*22 
or CYP3A4*1B alleles, resulting in reduced or increased expression 
of CYP3A4, respectively; however, these alleles cannot explain 
the inter-individual differences in CYP3A4 mRNA levels. For 
the categorization of the patients regarding CYP3A4 expression, 
more useful information can be obtained from CYP3A4 mRNA 
levels than from CYP3A4 genotyping. CYP3A4 expression assays 
revealed that about two-thirds of the patients expressed CYP3A4 
at normal level, approximately 30% was low CYP3A4 expressers, 
and 3 patients displayed high CYP3A4 expression (Table 1). One 
of the high CYP3A4 expressers carried CYP3A5*1, anticipating 
rapid metabolism of CYP3A substrates. Strong association was 
found between the patients’ CYP3A4 expression and normalized 
clozapine serum levels (Figure  2A). In CYP3A5 nonexpressers, 
the normalized concentrations were significantly higher in those 
displaying low CYP3A4 mRNA levels than in normal or high 
CYP3A4 expressers (185.53 ± 56.53 vs 78.05 ± 29.57 or 66.52 ± 0.25 
(ng/mL)/(mg/kg), P < .0001). The patients’ CYP3A5 genotype was 
significantly associated with clozapine concentrations in those 
patients who expressed CYP3A4 at low levels (P < .0001). Further 
confirmation of the role of CYP3A5 is needed because of the rela-
tively small number of CYP3A5 expressers.
According to the present results, the patients’ CYP2C19 or 
CYP2D6 genotypes and CYP1A2 expression seemed to have no 
effect on clozapine concentrations, whereas CYP3A4 expres-
sion significantly influenced the steady-state levels of clozap-
ine. The patients were divided into 4 groups according to the 
CYP3A5 genotype (CYP3A5 expressers, nonexpressers) and 
CYP3A4 expression (low, normal, and high). Significantly higher 
(about 2-fold) clozapine concentration was observed in CYP3A5 
nonexpresser patients displaying low CYP3A4 expression than 
in all the others (Figure 2A). However, modelling of the associa-
tion between CYP3A4 expression and clozapine concentrations 
identified only 2 groups. The first group consisted of the CYP3A5 
nonexpressers with low CYP3A4 mRNA levels, whereas the 
remaining 3 combinations (normal and high CYP3A4 express-
ers with CYP3A5*3/*3 genotype, and patients with CYP3A5*1/*3 
genotype) were grouped, since the separate models for these 
combinations did not result in significantly different parame-
ters. The same model was applied for the 2 groups; however, the 
model parameter values were different (ko and k1, Figure 2B). The 
models were able to predict the normalized clozapine concen-
trations with the standard deviations of 15.68 and 6.65 ng/mL for 
the low CYP3A4 expressers with CYP3A5*3/*3 genotype and the 
rest of the patients, respectively.
Optimization of Clozapine Dose
According to the consensus guideline (Hiemke et  al., 2011), a 
clozapine concentration between 350 and 600 ng/mL is recom-
mended for the treatment of schizophrenia; however, lower 
serum concentrations (200–300 ng/mL) were demonstrated to be 
as effective as high concentrations (300–450 ng/mL) (Zwaag et al, 
1996; Ulrich et al, 2003). Therefore, the concentration of 200 ng/
mL was considered as the lower threshold. The 2 models for 
prediction of clozapine concentration in the patients expressing 
CYP3A4 at low or normal/high levels had comparable prediction 
quality (Figure 2B) and were found to be applicable for predic-
tion of optimal dosing. The dose requirement for therapeutic 
concentration was predicted for each patient setting the mini-
mal dose adjustment to 12.5 mg (the lowest content of clozapine 
products available is 25 mg, and the pills can be split in half) 
(Figure 3A). The models proposed significantly lower daily dose 
for the patients expressing CYP3A4 at a low level than for those 
with normal/high CYP3A4 mRNA levels or with CYP3A5*1/*3 
genotype (the dose range of 51.04–258.33 vs 227.39–586.38 mg/d; 
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P < .0001), whereas the actual dosage applied for low and normal/
high CYP3A4 expresser patients or CYP3A5 expressers was iden-
tical (245.37 ± 158.88 vs 208.98 ± 120.69 mg/d; P = .4166). In 38% of 
the patients, the clozapine daily dose was found to be out of 
the dose range predicted by the models, that is, approximately 
one-third of the patients might have received inadequate doses. 
Figure 1. The influence of the patients’ CYP2C19 (A), CYP2D6 genotypes (B), and CYP1A2 expression (C) on serum clozapine concentrations. GAPDH, glyceraldehide 
3-phosphate dehydrogenase; mut, loss-of-function CYP allele; ×N, allele duplication.
Figure 2. The influence of the patients’ CYP3A4 expression and CYP3A5 genotype on serum clozapine concentrations. (A) Clozapine concentrations normalized by the 
dose and the bodyweight in CYP3A5 expressers (CYP3A5*1/*3) and nonexpresser patients expressing CYP3A4 at low, normal, and high levels, and (B) linear models for 
low (triangles) and normal/high (points) CYP3A4 expresser patients. The black points (A) indicate low CYP3A4 expresser patients carrying CYP3A5*1. The white point 
(A) indicates a high CYP3A4 expresser patient carrying CYP3A5*1. *P < .0001. GAPDH, glyceraldehide 3-phosphate dehydrogenase.
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Underdosing occurred more frequently, primarily in the patients 
expressing CYP3A4 at a normal/high level or in CYP3A5 express-
ers (Figure 3A). Moreover, the routine dosing regimen appears 
to be appropriate for the patients with low CYP3A4 mRNA 
levels rather than for normal/high expressers. Seven of the 24 
low expresser patients were overdosed, whereas the clozapine 
therapy of 17 patients (71%) in the low CYP3A4 expresser group 
resulted in therapeutic concentrations of clozapine. The math-
ematical model displayed clozapine dosing to be optimal for 
40 patients in the normal/high CYP3A4 expresser and CYP3A5 
expresser groups (n = 68), whereas 41% were underdosed. An 
additional approach was also applied for the calculation of clo-
zapine dose requirement for the therapeutic concentrations, 
and we inferred the dose requirement from the dosing applied 
in those patients who displayed clozapine concentrations in the 
range of 200 to 600 ng/mL (Figure 3B). The low CYP3A4 expresser 
patients required a significantly lower (50%) dose of clozapine 
for the optimal serum level than normal/high CYP3A4 express-
ers (2.18 ± 0.64 mg/kg vs 4.98 ± 1.40 mg/kg; P < .0001) (Figure 3B).
Clozapine Metabolite Concentrations in Patients 
with Various CYP3A4 Expression
Several CYPs are assumed to be responsible for the formation of 
norclozapine, while CYP3A4 is likely to catalyze the clozapine 
N-oxidation. The formation of both principal metabolites widely 
varied in individuals (Table 1); however, the serum concentrations 
of clozapine metabolites appeared to be associated merely with 
the patients’ CYP3A4 expression and not with CYP1A2 mRNA 
levels. Strong association was observed between the metabo-
lite/clozapine ratios and CYP3A4 mRNA levels. The patients 
who expressed CYP3A4 at a low level displayed significantly 
lower norclozapine/clozapine ratios than the CYP3A4 normal/
high expressers or those who carry CYP3A5*1 (0.5521 ± 0.1535 vs 
0.7655 ± 0.2088; P < .0001) (Figure 4A). Furthermore, significantly 
lower clozapine N-oxide/clozapine ratios were observed in the 
patients displaying low CYP3A4 expression than in CYP3A4 nor-
mal/high expressers (0.2279 ± 0.0887 vs 0.5659 ± 0.1960, P < .0001) 
(Figure 4B). The strong association between the patients’ CYP3A 
status and the serum clozapine concentrations or the metabo-
lite/clozapine ratios demonstrated the potential role of CYP3A 
enzymes in clozapine clearance. Nevertheless, the norclozap-
ine/clozapine concentration ratios were comparable in patients 
expressing CYP1A2 at a low or normal level (0.6988 ± 0.2341 vs 
0.7070 ± 0.1824; P = 0.3966).
Discussion
Clozapine is extensively metabolized, and approximately 2% of 
the administered dose is excreted as unchanged parent com-
pound (Dain et al., 1997). The plasma concentration in patients 
is strongly influenced by their clozapine-metabolizing capacity; 
therefore, therapeutic drug monitoring for clozapine is strongly 
recommended to avoid the risk of intolerance/intoxication or 
the risk of relapse due to subtherapeutic clozapine plasma con-
centration (Hiemke et al., 2011). Several patient-related factors 
(gender, age, smoking behavior) have been reported to influence 
the elimination of clozapine; however, the significance of the 
associations between these factors and clozapine concentra-
tions varies from cohort to cohort and often depends on data 
normalization (Haring et  al., 1989, 1990; Tang et  al., 2007). In 
addition to gender, age, and smoking, disease and co-medica-
tion can also modify patients’ drug-metabolizing activity due to 
the phenoconversion of CYP enzyme(s) (Shah and Smith, 2015). 
The role of several CYP enzymes in clozapine metabolism has 
been assumed; however, the dosing strategy applied in clinical 
practice does not routinely take the patients’ CYP status into 
consideration, because the clinical relevance of these CYPs has 
not been clearly evidenced.
In vitro studies using cDNA-expressed CYP enzymes have 
demonstrated the contribution of CYP1A2, CYP2C19, CYP3A4, 
and CYP2D6 to clozapine metabolism (Linnet and Olesen, 1997; 
Fang et  al., 1998; Olesen and Linnet, 2001); however, hepatic 
microsomal metabolism hardly supported a significant role of 
CYP2C19 and CYP2D6 (Fang et al., 1998; Tugnait et al., 1999). Our 
results indicated that CYP2C19 and CYP2D6 were not likely to 
have a primary role in clozapine clearance. These findings are 
consistent with the results of previous studies showing that the 
Figure 3. The influence of the patients’ CYP3A4 expression on clozapine dose requirements. (A) Dose requirements for therapeutic concentration of clozapine cal-
culated from the models (bars) and applied clozapine doses (points) in low and normal/high CYP3A4 expresser patients, and (B) dose requirements calculated from 
applied doses in the patients displaying therapeutic concentrations of clozapine (200–600 ng/mL). *P < .0001. GAPDH, glyceraldehide 3-phosphate dehydrogenase.
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patients’ response to clozapine treatment did not correlate with 
their CYP2D6 genotype (Arranz et al., 1995), and the association 
between clozapine clearance in patients and the polymorphic 
expression of either CYP2D6 or CYP2C19 have failed to be dem-
onstrated (Dahl et al., 1994). In contrast, Jaquenoud-Sirot et al. 
(2009) reported higher clozapine concentrations in patients with 
CYP2C19*2/*2 genotype than in those carrying non-CYP2C19*2/*2 
genotypes. For normalization of clozapine concentrations, 
Jaquenoud-Sirot et  al. (2009) did not take the patients’ body-
weight into account, which can influence the interpretation and 
the comparison of patients’ clozapine concentrations.
CYP1A2 is considered to be one of the major enzymes respon-
sible for clozapine biotransformation (Eiermann et al., 1997; Fang 
et  al., 1998; Olesen and Linnet, 2001), which was confirmed by 
several clinical data. Induction of CYP1A2 by the components of 
cigarette smoke seems to increase clozapine dose requirement, pri-
marily of male smokers (Haring et al., 1989; Tang et al., 2007); how-
ever, the patients with the polymorphic CYP1A2*1F allele, resulting 
in an increase in CYP1A2 inducibility, did not require dose adjust-
ment (Weide et al., 2003). On the other hand, Ferrari et al. (2012) 
demonstrated an association between the frequency of clozapine-
induced adverse reactions and the occurrence of the low activity 
CYP1A2*1C allele in patients. The CYP1A2 substrate caffeine has 
been reported to inhibit clozapine metabolism, and caffeine con-
sumption in a daily dose of 400 to 1000 mg significantly decreased 
clozapine clearance (Hagg et  al., 2000; Raaska et  al., 2004). The 
adjunctive fluvoxamine to ongoing clozapine therapy was found 
to increase clozapine plasma concentration, moreover resulting in 
toxic serum concentration, which was attributed to CYP1A2 inhi-
bition by fluvoxamine (Hiemke et al., 1994; Szegedi et al., 1999; Lu 
et al., 2004). It should be noted that fluvoxamine is not a CYP1A2-
selective inhibitor, but significantly blocks the activities of other 
CYPs (Kashuba et al., 1998), notably it irreversibly inhibits CYP3A4 
by forming a metabolic intermediate complex (Jones et al., 2007).
The clinical observations on the dominant role of CYP1A2 
were not confirmed by our findings that the patients’ CYP3A sta-
tus rather than their CYP1A2 expression was associated with 
normalized clozapine concentrations. The relative importance of 
CYP3A4 in clozapine clearance, particularly in patients with low 
CYP1A2 activity, may be higher than it has been previously con-
sidered (Eiermann et al., 1997; Olesen and Linnet, 2001). Chetty 
and Murray (2007) suggested further research with the potential 
to demonstrate the critical roles of CYPs other than CYP1A2 for 
the elucidation of individual differences in clozapine metabo-
lism. The following indirect evidences can predict the potential 
role of CYP3A4: (1) clozapine N-demethylation to norclozapine 
significantly correlated with CYP3A4-selective midazolam clear-
ance (Ghassabian et al., 2010); (2) concomitant treatment with 
CYP3A4 inducers, such as carbamazepine, rifampicin, or phe-
nytoin, was observed to substantially reduce clozapine concen-
trations (Miller, 1991; Jerling et  al., 1994; Tiihonen et  al., 1995; 
Peritogiannis et al., 2007; Parker, 2016); and (3) initiation of the 
CYP3A4 inhibitor erythromycin therapy increased clozapine lev-
els and evoked toxic symptoms (Cohen et al., 1996). Furthermore, 
Zhang et al. (2008) provided support for the functional roles of 
both CYP3A4 and CYP1A2 in clozapine clearance, and suggested 
that the relative activities of CYP3A4 and CYP1A2 in patients 
might determine the clearance pathways. Although the majority 
of the patients with schizophrenia were smokers evoking high 
CYP1A2 activity (Leon and Diaz, 2005), in the present study, only 
38% of the patients were current smokers and 4 subjects (4.3%) 
were heavy smokers (>20 cigarettes/d). In >70% of the patients, 
CYP1A2 mRNA was expressed at low concentration, whereas 
a high proportion of the patients (>70%) were CYP3A4 normal/
high expressers, and additionally 3 low CYP3A4 expressers dis-
played normal clozapine-metabolizing capacity because of the 
functional CYP3A5*1 allele. Therefore, the relative CYP activities 
predicted the potential role of CYP3A4/5 in clozapine clearance, 
which was confirmed by the 2-fold higher normalized clozap-
ine concentrations and by the halved dose-requirement in low 
CYP3A4 expressers.
Since the majority of the patients were on multi-drug ther-
apy, co-medication as one of the main factors resulting in phen-
oconversion of drug-metabolizing enzymes must be considered. 
Haloperidol, risperidone, and propranolol are potent CYP2D6 
inhibitors that may influence the minor contribution of CYP2D6 
to clozapine clearance (Shin et  al., 1999; Obach et  al, 2006); 
however, most of the patients who were co-treated with these 
drugs carried the CYP2D6 loss-of-function allele. Genetic factors 
and/or co-medication therefore could result in CYP2D6 poor 
metabolism. According to the guidance of the Pharmacogenetic 
Working Group of the Royal Dutch Pharmacists Association, no 
clozapine dose adjustment is needed for patients with CYP2D6 
poor metabolism (Samer et al., 2013). Valproate has been proved 
to transcriptionally induce CYP3A4 expression (Cerveny et al., 
2007); consequently, the patients’ CYP3A4 mRNA levels captured 
Figure 4. The influence of the patients’ CYP3A4 expression on the metabolite/clozapine concentration ratios. (A) Norclozapine/clozapine concentrations, and (B) clo-
zapine N-oxide/clozapine concentrations in patients with various CYP3A4 expression. *P < .0001. GAPDH, glyceraldehide 3-phosphate dehydrogenase.
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the influence of valproate treatment. The patients’ caffeine con-
sumption data were not available, and the CYP1A2 inhibitory 
effect on clozapine clearance therefore could not be taken into 
account.
Approximately 30% of the patients were underdosed, dis-
playing lower clozapine concentration than required for the 
optimal therapeutic effect because of rapid elimination of the 
drug. However, it should be noted that none of the patients 
were in acute phase, and the majority of the subjects were in a 
relatively stable state, which was a consequence of the inclu-
sion criteria of unmodified antipsychotic doses for at least 2 
weeks. Therefore, the clinical relevance of this underdosing 
may be minor. Additionally, the normal/high CYP3A4 activ-
ity was associated with increased metabolite formation, that 
is, the concentrations of norclozapine and clozapine N-oxide 
were close to or even exceeded clozapine concentrations. 
While N-oxidation of clozapine is the inactivation pathway 
of metabolism, the N-demethylated metabolite exhibits some 
pharmacological effects and contributes to the overall efficacy 
of clozapine (Wenthur and Lindsley, 2013). Furthermore, high 
norclozapine level has been associated with an increased risk 
of weight gain and seizure, because it is a more potent 5-HT2C 
antagonist than clozapine (Kuoppamaki et al., 1993; Lu et al., 
2004; Polcwiartek and Nielsen, 2016). Therefore, the clinical 
outcome seemed to be predictable from norclozapine/clozap-
ine ratios rather than from the absolute concentration of clo-
zapine (Weiner et al., 2004; Lameh et al., 2007). Consequently, 
lower clozapine clearance resulting in lower norclozapine/clo-
zapine ratios has some clinical benefit over rapid metabolism 
(Légaré et al., 2013).
In conclusion, the patients’ clozapine-metabolizing capacity 
is influenced by genetic and plenty of nongenetic factors, and the 
expression/activity of clozapine-metabolizing enzymes can be a 
useful predictor for the individual clozapine concentration and 
dose requirement. Although the present work involved a limited 
number of patients and further investigation enrolling larger 
cohort is required, it clearly demonstrated that CYP3A status 
could be the major determinant of normalized clozapine con-
centration and dose requirement, in particular that the patients 
expressed CYP1A2 at a relatively low level. For achieving the 
therapeutic concentration, twice as high a dose was necessary 
for the normal/high CYP3A4 expressers and CYP3A5*1 carriers 
than for low CYP3A4 expressers. Tailored medication controlled 
by patients’ CYP3A4 expression and CYP3A5 genotype may facili-
tate the improvement of the individual clozapine therapy, lead-
ing to the dosage optimization for a more effective therapy.
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